Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

被引：32
|
作者：
Tiacci, Enrico [1 ]
De Carolis, Luca [1 ]
Simonetti, Edoardo [1 ]
Merluzzi, Mara [1 ]
Bennati, Antonio [1 ]
Perriello, Vincenzo Maria [1 ]
Pucciarini, Alessandra [1 ]
Santi, Alessia [1 ]
Venanzi, Alessandra [1 ]
Pettirossi, Valentina [1 ]
Schiavoni, Gianluca [1 ]
Tasselli, Luisa [1 ]
Ascani, Stefano [2 ,3 ]
Volpetti, Stefano [4 ]
Falini, Brunangelo [1 ]
机构：
[1] Univ & Hosp Perugia, Hematol, Perugia, Italy
[2] Univ Perugia, Anat Pathol, Perugia, Italy
[3] Hosp Terni, Perugia, Italy
[4] Azienda Sanitaria Univ Integrata, Clin Ematol, Udine, Italy
来源：
LEUKEMIA | 2021年 / 35卷 / 11期
基金：
欧洲研究理事会;
关键词：
MELANOMA; VEMURAFENIB; DIAGNOSIS; THERAPY;
D O I：
10.1038/s41375-021-01210-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：3314 / 3318
页数：5
相关论文
共 50 条
  • [1] Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
    Enrico Tiacci
    Luca De Carolis
    Edoardo Simonetti
    Mara Merluzzi
    Antonio Bennati
    Vincenzo Maria Perriello
    Alessandra Pucciarini
    Alessia Santi
    Alessandra Venanzi
    Valentina Pettirossi
    Gianluca Schiavoni
    Luisa Tasselli
    Stefano Ascani
    Stefano Volpetti
    Brunangelo Falini
    Leukemia, 2021, 35 : 3314 - 3318
  • [2] Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial
    Tiacci, Enrico
    De Carolis, Luca
    Zinzani, Pier Luigi
    Pulsoni, Alessandro
    Zaja, Francesco
    Cimminiello, Michele
    Ambrosetti, Achille
    Rossi, Davide
    Motta, Giovanna
    Varettoni, Marzia
    Fraticelli, Vincenzo
    Carella, Angelo Michele
    Anastasia, Antonella
    Leoni, Pietro
    Rambaldi, Alessandro
    Pileri, Stefano Aldo
    Foa, Robin
    Falini, Brunangelo
    BLOOD, 2014, 124 (21)
  • [3] Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia
    Park, Jae H.
    Chung, Stephen S.
    Chung, Young Rock
    Won, Helen
    Teruya-Feldstein, Julie
    Berger, Michael
    Khawaja, Talal T.
    Lacouture, Mario E.
    Levine, Ross L.
    Abdel-Wahab, Omar
    Tallman, Martin S.
    BLOOD, 2013, 122 (21)
  • [4] THE BRAF INHIBITOR VEMURAFENIB IS SAFE AND HIGHLY EFFECTIVE IN REFRACTORY AND RELAPSED HAIRY CELL LEUKEMIA: RESULTS OF THE HCL-PG01 PHASE-2 ITALIAN CLINICAL TRIAL
    Tiacci, E.
    De Carolis, L.
    Broccoli, A.
    Pulsoni, A.
    Mazzucco, M.
    Cimminiello, M.
    Ambrosetti, A.
    Rossi, D.
    Motta, G.
    Varettoni, M.
    Fraticelli, V.
    Carella, A. M.
    Anastasia, A.
    Leoni, P.
    Rambaldi, A.
    Falzetti, F.
    Ascani, S.
    Capponi, M.
    Martelli, M. P.
    Pileri, S. A.
    Foa, R.
    Zinzani, P. L.
    Falini, B.
    HAEMATOLOGICA, 2015, 100 : 1 - 2
  • [5] Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib
    V. Vergote
    D. Dierickx
    A. Janssens
    G. Verhoef
    T. Tousseyn
    P. Vandenberghe
    P. Wolter
    M. Delforge
    Annals of Hematology, 2014, 93 : 2087 - 2089
  • [6] Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib
    Vergote, V.
    Dierickx, D.
    Janssens, A.
    Verhoef, G.
    Tousseyn, T.
    Vandenberghe, P.
    Wolter, P.
    Delforge, M.
    ANNALS OF HEMATOLOGY, 2014, 93 (12) : 2087 - 2089
  • [7] Cotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib
    Blachly, James S.
    Lozanski, Gerard
    Lucas, David M.
    Grever, Michael R.
    Kendra, Kari
    Andritsos, Leslie A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (01): : 9 - 13
  • [8] Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)
    Tiacci, Enrico
    De Carolis, Luca
    Capponi, Monia
    Falcinelli, Flavio
    Zaja, Francesco
    Pulsoni, Alessandro
    Simonetti, Edoardo
    Montechiarello, Elisa
    Romano, Alessandra
    Olivieri, Jacopo
    Mancini, Alessandro
    D'Elia, Gianna Maria
    Foa, Robin
    Frezzato, Maurizio
    Falini, Brunangelo
    BLOOD, 2023, 142
  • [9] VEMURAFENIB IS SAFE AND HIGHLY ACTIVE IN HAIRY CELL LEUKEMIA PATIENTS REFRACTORY TO OR RELAPSED AFTER PURINE ANALOGS: A PHASE-2 ITALIAN CLINICAL TRIAL
    Tiacci, E.
    De Carolis, L.
    Zinzani, P. L.
    Pulsoni, A.
    Mazzucco, M.
    Cimminiello, M.
    Ambrosetti, A.
    Rossi, D.
    Motta, G.
    Varettoni, M.
    Fraticelli, V.
    Carella, A. M.
    Anastasia, A.
    Leoni, P.
    Rambaldi, A.
    Pileri, S. A.
    Foa, R.
    Falini, B.
    HAEMATOLOGICA, 2014, 99 : 245 - 246
  • [10] Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib
    Andritsos, Leslie A.
    Blachly, James S.
    Kendra, Kari
    Lozanski, Gerard
    Greyer, Michael R.
    BLOOD, 2013, 122 (21)
12345